Meitav Investment House’s CollPlant Biotechnologies CLGN Stock Holding History

Meitav Investment House’s Portfolio CLGN Stock Details CLGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-547,730	Closed	-$11.6M	–	409
2021 Q2	$11.6M	Hold	547,730	–	–	0.3%	81
2021 Q1	$7.36K	Hold	547,730	–	–	0.21%	102
2020 Q4	$5.9M	Hold	547,730	–	–	0.23%	85
2020 Q3	$4.57M	Buy	547,730 +125,958	+30%	+$1.13M	0.23%	82
2020 Q2	$4.21M	Buy	421,772 +312,231	+285%	+$3.21M	0.25%	74
2020 Q1	$1.01M	Buy	+109,541	New	+$1.12M	0.08%	145
2019 Q2	–	Sell	-141,889	Closed	-$780K	–	435
2019 Q1	$780K	Buy	141,889 +227	+0.2%	+$1.21K	0.04%	194
2018 Q4	$594K	Buy	+141,662	New	+$739K	0.04%	186

Other funds holding CLGN

IMOV

Investment Management of Virginia Richmond, Virginia $526M AUM 3.23% 1-Year Est. Return

RAM

Roumell Asset Management Chevy Chase, Maryland $53.3M AUM 8.91% 1-Year Est. Return

SDJVC

St. Denis J. Villere & Co New Orleans, Louisiana $907M AUM 10.61% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

BFEC

Benjamin F. Edwards & Company St. Louis, Missouri $5.69B AUM 15.37% 1-Year Est. Return

Weil Company San Diego, California $445M AUM 14.95% 1-Year Est. Return

Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return

SPC

Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return

Meitav Investment House's CLGN Position: Q3 2021 in Review

Meitav Investment House sold out of CollPlant Biotechnologies (CLGN) in Q3 2021, closing a stake of 547,730 shares — an estimated $11.6M sold.

Meitav Investment House first reported a position in CLGN in Q4 2018 and held it in 8 quarters. The position peaked at $11.6M in Q2 2021. 15 funds tracked by Wall St. Rank hold CLGN as of Q3 2021.

Meitav Investment House reported no remaining CollPlant Biotechnologies position as of Q3 2021 after selling out during the quarter.
Meitav Investment House sold 547,730 CollPlant Biotechnologies shares in Q3 2021, an estimated $11.6M.
Meitav Investment House first reported a position in CollPlant Biotechnologies in Q4 2018 and held it in 8 quarters.
Meitav Investment House's CollPlant Biotechnologies position peaked at $11.6M in Q2 2021.
15 funds tracked by Wall St. Rank held CollPlant Biotechnologies as of Q3 2021.

Based on Meitav Investment House's 13F filing for Q3 2021, filed 3 Nov 2021.